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Abstract
Background:  It is generally assumed that inflammatory bowel disease (IBD)-related
carcinogenesis occurs as a result of chronic inflammation. We previously developed a novel colitis-
related mouse colon carcinogenesis model initiated with azoxymethane (AOM) and followed by
dextran sodium sulfate (DSS). In the present study we investigated whether a cyclooxygenase
(COX)-2 inhibitor nimesulide and ligands for peroxisome proliferator-activated receptors
(PPARs), troglitazone (a PPARγ  ligand) and bezafibrate (a PPARα  ligand) inhibit colitis-related colon
carcinogenesis using our model to evaluate the efficacy of these drugs in prevention of IBD-related
colon carcinogenesis.
Methods: Female CD-1 (ICR) mice were given a single intraperitoneal administration of AOM (10
mg/kg body weight) and followed by one-week oral exposure of 2% (w/v) DSS in drinking water,
and then maintained on the basal diets mixed with or without nimesulide (0.04%, w/w), troglitazone
(0.05%, w/w), and bezafibrate (0.05%, w/w) for 14 weeks. The inhibitory effects of dietary
administration of these compounds were determined by histopathological and
immunohistochemical analyses.
Results: Feeding with nimesulide and troglitazone significantly inhibited both the incidence and
multiplicity of colonic adenocarcinoma induced by AOM/DSS in mice. Bezafibrate feeding
significantly reduced the incidence of colonic adenocarcinoma, but did not significantly lower the
multiplicity. Feeding with nimesulide and troglitazone decreased the proliferating cell nuclear
antigen (PCNA)-labeling index and expression of β -catenin, COX-2, inducible nitric oxide synthase
(iNOS) and nitrotyrosine. The treatments increased the apoptosis index in the colonic
adenocarcinoma. Feeding with bezafibrate also affected these parameters except for β -catenin
expression in the colonic malignancy.
Conclusion:  Dietary administration of nimesulide, troglitazone and bezafibrate effectively
suppressed the development of colonic epithelial malignancy induced by AOM/DSS in female ICR
mice. The results suggest that COX-2 inhibitor and PPAR ligands could serve as an effective agent
against colitis-related colon cancer development.
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Background
Colorectal cancer (CRC) is one of the leading causes of
death in the world. This malignancy is also one of the
most serious complications of inflammatory bowel dis-
ease (IBD), including ulcerative colitis (UC) and Crohn's
disease [1]. Long-term UC patients have an increased risk
of developing CRC compared with the general population
[2]. The precise mechanisms of the IBD-related carcino-
genesis process are largely unclear, although it is generally
assumed that IBD-related carcinogenesis occurs as a result
of chronic inflammation [3].
Several agents, such as folic acid, short chain fatty acid
(butyrate), ursodeoxycholic acid, and 5-aminosalicylic
acid, have been suggested to be useful for prevention of
CRC in UC [4]. Epidemiological studies have shown that
prolonged use of aspirin is associated with a reduced risk
of CRC [5]. Consistent with these data, several non-steroi-
dal anti-inflammatory drugs (NSAIDs), including
cyclooxygenase (COX)-2 inhibitors, suppressed the devel-
opment of chemically-induced colon carcinomas in rats
[6] and intestinal polyps in Min mice with a nonsense
mutation of the Apc gene [7]. In addition, clinical trials
have demonstrated that a NSAID sulindac causes regres-
sion of adenomas in patients with familial adenomatous
polyposis [8]. Nimesulide (4-nitro-2-phenoxymeth-
anesulfonanilide), a selective inhibitor of COX-2, belong-
ing to the sulfonamide class [9], is less ulcerogenic than
other NSAIDs [10], and suppresses the formation of aber-
rant crypt foci (ACF), being putative precancerous lesions
of the colon cancer, induced by a colon carcinogen,
azoxymethane (AOM) in rats [11]. Moreover, this COX-2
inhibitor could effectively reduce the development of
intestinal polyps in Min mice [12].
Peroxisome proliferator-activated receptors (PPARs?) are
ligand-activated transcription factors, belonging to the
nuclear hormone receptor superfamily [13]. Three PPAR
isotypes, PPARα , PPARδ (β ), and PPARγ , have been identi-
fied. PPARγ  is highly expressed in fat tissue, and play
important roles in adipocyte differentiation and lipid
storage [14]. PPARγ  is also expressed in a number of epi-
thelial neoplasms, such as cancers in colon, breast, and
prostate [13]. PPARγ  ligands, including thiazolidinedi-
ones (troglitazone and rosiglitazone) and tyrosine ana-
logue (GW7845), can induce apoptosis and adipogenic
differentiation, and inhibit tumor growth both in vitro
and in vivo studies [15-17]. We previously reported that
pioglitazone, bezafibrate or troglitazone in diet are able to
suppress ACF formation induced by dextran sodium sul-
fate (DSS)/AOM in the rat colon [18]. Osawa et al. [19]
confirmed our findings by demonstrating that ligands for
PPARγ  (troglitazone, rosiglitazone, and pioglitazone)
suppress the occurrence of colonic tumors in mice initi-
ated with AOM. Niho et al. [20] also demonstrated that
ligands for PPARα  (bezafibrate) and PPARγ  (pioglita-
zone) suppress intestinal polyp formation in Apc-deficient
mice. Moreover, PPARγ  could suppress β -catenin levels
and colon carcinogenesis during the early steps of tumor
formation [21]. On the other hand, high doses of troglita-
zone and rosiglitazone can promote polyp formation in
the Min mouse colon [22,23].
For understanding the pathogenesis of IBD and IBD-
related CRC, several animal models have been estab-
lished. Most used is a mouse model with DSS [24]. Mod-
ifying effects of several xenobiotics on IBD-related colon
carcinogenesis were reported [25] in animal models of
IBD. However, the colitis model using DSS with or with-
out carcinogen needs to a long period and repeated
administration of DSS to induce colitis and colitis-related
CRC. Recently, an endogenous anti-inflammatory PPARγ
pathway was suggested in the intestine, which was found
in PPARγ -deficient mice [26,27]. To search novel and
effective chemopreventive agents against IBD-related
CRC, we recently have developed a novel colitis-related
CRC mouse model, in which large bowel adenocarcino-
mas occur within 20 weeks and their histology and bio-
logical characteristics are resemble to those found in
human cased [28]. As a part of our search for a safer che-
mopreventive agent for colitis-related colon cancer, in the
present study we examined the chemopreventive ability of
nimesulide, troglitazone, and bezafibrate using our
mouse colon carcinogenesis model for colitis-related
colon carcinogenesis [28].
Methods
Animals, chemicals and diets
Female Crj: CD-1 (ICR) (Charles River Japan Inc., Tokyo,
Japan) aged 5 weeks were used in this study. They were
maintained at Kanazawa Medical University Animal Facil-
ity according to the Institutional Animal Care Guidelines.
The mice were quarantined for the first 7 days then rand-
omized by body weight into experimental and control
groups. All animals were housed in plastic cages (five or
six mice/cage) with free access to drinking water and a pel-
leted basal diet, CRF-1 (Oriental Yeast Co., Ltd., Tokyo,
Japan), under controlled conditions of humidity (50 ±
10%), light (12/12 hour light/dark cycle) and tempera-
ture (23 ± 2°C). A colonic carcinogen AOM was pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA).
DSS with a molecular weight of 40,000 was purchased
from ICN Biochemicals, Inc. (Aurora, OH, USA). DSS for
induction of colitis was dissolved in distilled water at a
concentration of 2% (w/v). Nimesulide was purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Troglita-
zone and bezafibrate were kindly supplied by Sankyo Co.
(Tokyo, Japan) and Kissei Pharmaceutical Co. (Mat-
sumoto, Japan), respectively. Experimental diet contain-
ing nimesulide (0.04%, w/w), troglitazone (0.05%, w/w)BMC Cancer 2005, 5:46 http://www.biomedcentral.com/1471-2407/5/46
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or bezafibrate (0.05%, w/w) was prepared every week by
mixing the respective compound in powdered basal diet
CRF-1. The dose levels were determined on the basis of
previous studies [18,29].
Experimental procedure
A total of 71 female ICR mice were divided into 7 experi-
mental and control groups (Figure 1). Mice in groups 1
through 4 were given a single intraperitoneal injection of
AOM (10 mg/kg body weight). Starting one week after the
AOM injection, animals in group 1 were administered to
2%DSS in drinking water for 7 days, and then followed
without any further treatment for 15 weeks. Mice in
groups 2, 3, and 4 were fed the diets containing 0.04%
nimesulide, 0.05% troglitazone, and 0.05% bezafibrate,
respectively, for 14 weeks, starting 1 week after the stop of
DSS administration. Animals in groups 5, 6, and 7 were
respectively given the diets containing 0.04% nimesulide,
0.05% troglitazone, and 0.05% bezafibrate alone for 14
weeks. Group 8 was given a single dose of AOM. Group 9
was given 2% DSS for 7 days. Group 10 consisted of
untreated mice. All animals were sacrificed at the end of
the study (Week 17) by ether overdose. Their large bowels
were flushed with saline, excised, measured their length
(from ileocecal junction to the anal verge), cut open lon-
gitudinally along the main axis, and then washed with
Experimental protocol Figure 1
Experimental protocol. Arrows, AOM 10 mg/kg body weight, i.p. injection; densely cross-hatched bars, 2% dextran sodium sul-
fate (DSS) in drinking water; open bars, basal diet and tap water; crosses, death.
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saline. The large bowels were macroscopically inspected,
cut, and fixed in 10% buffered formalin for at least 24
hours. Histopathological examination was performed on
paraffin-embedded sections after hematoxylin and eosin
(H & E) staining. Colonic mucosal dysplasia (mild- and
severe-graded) was diagnosed according to the criteria
described by Ridell et al. [30] and Pascal [31]. Colonic
neoplasms were diagnosed according to the description
by Ward [32].
Immunohistochemistry
Immunohistochemistry for the proliferating cell nuclear
antigen (PCNA), apoptotic nuclei, β -catenin, COX-2,
inducible nitric oxide synthase (iNOS), and nitrotyrosine
was performed on 4-µm-thick paraffin-embedded sec-
tions from colons of mice in each group by the labeled
streptavidin biotin method using a LSAB KIT (DAKO
Japan, Kyoto, Japan) with microwave accentuation. The
paraffin-embedded sections were heated for 30 min at
65°C, deparaffinized in xylene, and rehydrated through
graded ethanol at room temperature. A 0.05 M Tris HCl
buffer (pH 7.6) was used to prepare solutions and for
washes between various steps. Incubations were per-
formed in a humidified chamber. For the determination
of PCNA-incorporated nuclei, the PCNA-immunohisto-
chemistry was performed according to the method
described by Watanabe et al. [33]. Apoptotic index was
also evaluated by immunohistochemistry for single
stranded DNA (ssDNA) [33]. Sections were treated for 40
min at room temperature with 2% BSA and incubated
overnight at 4°C with primary antibodies. Primary anti-
bodies included anti-PCNA mouse monoclonal antibody
(diluted 1:50; PC10, DAKO Japan), anti-ssDNA rabbit
polyclonal antibody (diluted 1:300, DAKO Japan), anti-β -
catenin mouse monoclonal antibody (diluted 1:1000,
Transduction Laboratories, Lexington, KY, USA), anti-
COX-2 rabbit polyclonal antibody (diluted 1:50, IBL Co.,
Ltd., Gunma, Japan), anti-iNOS rabbit polyclonal anti-
body (diluted 1:1000, Wako Pure Chemical Industries,
Ltd., Osaka, Japan), and anti-nitrotyrosine rabbit polyclo-
nal antibody (diluted 1:500, Upstate Biotechnology, Lake
Placid, NY, USA). To reduce the non-specific staining of
mouse tissue by the mouse antibodies, a Mouse On
Mouse IgG blocking reagent (Vector Laboratories, Inc.,
Burlingame, CA, USA) was applied for 1 h. Horseradish
peroxidase activity was visualized by treatment with H2O2
and 3,3'-diaminobenzidine for 5 min. At the last step, the
sections were weakly counterstained with Mayer's hema-
toxylin (Merck Ltd., Tokyo, Japan). For each case, negative
controls were performed on serial sections. On the control
sections, incubation with the primary antibodies was
omitted.
Intensity and localization of immunoreactivities against
all primary antibodies used were examined on all sections
using a microscope (Olympus BX41, Olympus Optical
Co., Ltd., Tokyo, Japan). The PCNA and apoptotic indices
were determined by counting the number of positive cells
among at least 200 cells in the lesion, and were indicated
as percentages. Each slide for β -catenin, COX-2, iNOS,
and nitrotyrosine immunohistochemistry was evaluated
for intensity of immunoreactivity on a 0 to 4+ scale. The
overall intensity of the staining reaction was scored with 0
indicating no immunoreactivity and no positive cells, 1+
weak immunoreactivity and < 10% of positive cells, 2+
mild immunoreactivity and 10–30% of positive cells, 3+
moderate immunoreactivity and 31–60% of positive cells,
and 4+ strong immunoreactivity and 61–100% of positive
cells.
Statistical analysis
All measurements were compared by Student's t-test,
Welch's t-test or Fisher's exact probability test for paired
samples.
Table 1: Body, liver, relative liver weights, and length of colon.
Group no. Treatment No. of mice Body weight (g) Liver weight (g) Relative liver weight 
(g/100 g body weight)
Length of colon 
(cm)
1 AOM/DSS 10 36.6 ± 5.6 a 2.0 ± 0.5 5.5 ± 0.7 11.5 ± 2.1
2 AOM/DSS/0.04% Nimesulide 10 44.8 ± 5.6 b 2.3 ± 0.3 5.3 ± 0.7 12.1 ± 1.3
3 AOM/DSS/0.05% Troglitazone 10 43.6 ± 6.3 c 2.5 ± 0.5 d 5.7 ± 1.0 11.4 ± 1.1
4 AOM/DSS/0.05% Bezafibrate 10 42.4 ± 6.4 d 2.8 ± 0.7e 6.6 ± 1.5 12.1 ± 1.4
5 0. 04% Nimesulide 5 39.9 ± 7.3 2.0 ± 0.3 5.0 ± 0.9 12.5 ± 0.7
6 0. 05% Troglitazone 5 39.8 ± 4.0 2.1 ± 0.3 5.2 ± 0.7 11.9 ± 0.9
7 0. 05% Bezafibrate 5 46.8 ± 9.6 2.7 ± 0.5 5.8 ± 0.9 12.6 ± 1.4
8 AOM 5 42.8 ± 2.6 1.9 ± 0.1 4.5 ± 0.4 12.3 ± 1.2
9 DSS 6 34.4 ± 2.8f 1.8 ± 0.2 5.2 ± 0.7 12.3 ± 0.6
10 None 5 43.2 ± 6.5 2.0 ± 0.2 4.8 ± 0.8 12.0 ± 0.6
a Mean ± SD.
b-e Significantly different from group 1 by Student's t-test (b P < 0.005, c P < 0.02, d P < 0.05, and e P < 0.01).
f Significantly different from group 1 by Welch's t-test (f P < 0.05).BMC Cancer 2005, 5:46 http://www.biomedcentral.com/1471-2407/5/46
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Results
General observation
Bloody stool was noted in a few mice received 2% DSS
and their body weight gains were slightly decreased dur-
ing the period of the treatment. However, thereafter no
such clinical symptoms were observed. After Week 12,
anal prolapsus due to the tumor development in the distal
colon was found in a few mice treated with AOM and 2%
DSS (group 1). The body weights and lengths of large
bowel of mice in all groups at the end of the study are
shown in Table 1. The mean body weights of groups 2
(AOM/DSS/0.04% nimesulide, P < 0.005), 3 (AOM/DSS/
0.04% troglitazone, P < 0.02), and 4 (AOM/DSS/0.05%
bezafibrate, P < 0.05), were significantly higher than that
of group 1 (AOM/DSS). The mean body weight of group
9 (DSS alone, P < 0.05) was significantly lower than that
of group 10 (untreated). The mean liver weights of mice
in groups 3 (P < 0.05) and 4 (P < 0.01) were significantly
greater than that of group 1. However, there were no path-
ological alterations suggesting toxicity of test compounds
in the liver, kidneys, lung, and heart of mice (data not
shown).
Table 2: Incidence and multiplicity of colonic neoplasia.
Group 
no.
Treatment No. of 
mice
Incidence (no. of mice with neoplasms) Multiplicity (no. of tumors/mice, means ± SD)
Total Adenoma Adeno-carcinoma Total Adenoma Adeno-carcinoma
1 AOM/DSS 10 10/10 (100%) 10/10 (100%) 10/10 (100%) 5.2 ± 3.0 2.1 ± 1.8 3.0 ± 1.8
2A O M / D S S /
0.04% 
Nimesulide
10 8/10 (80%) 6/10 (60%)a 4/10 (40%)b 1.8 ± 1.7b 1.2 ± 1.3 0.6 ± 1.0c
3A O M / D S S /
0.05% 
Troglitazone
10 9/10 (90%) 9/10 (90%) 4/10 (40%)b 2.5 ± 1.8a 1.6 ± 1.1 1.2 ± 2.5a
4A O M / D S S /
0.05% 
Bezafibrate
10 8/10 (80%) 7/10 (70%) 6/10 (60%)a 2.6 ± 2.5a 1.1 ± 1.0a 1.8 ± 2.6
5 0.04% 
Nimesulide
5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
6 0.05% 
Troglitazone
5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
7 0.05% 
Bezafibrate
5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
8 AOM 5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
9 DSS 6 0/6 (0%) 0/6 (0%) 0/6 (0%) 0 0 0
10 None 5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
a,b,c Significantly different from group 1 by Fisher's exact probability test or Student's t-test (aP < 0.05, bP < 0.01, and c P < 0.005).
Table 3: Incidence of multiplicity colonic mucosal ulcer and dysplasia.
Group 
no.
Treatment Incidence (%) Multiplicity (no. of lesions / mouse, means ± SD)
Mucosal 
ulcer
Total 
dysplasia
Dysplasia with: Mucosal 
ulcer
Total 
dysplasia
Dysplasia with:
Mild 
atypia
Severe 
atypia
Mild 
atypia
Severe 
atypia
1 AOM/DSS 40% 90% 80% 50% 0.5 ± 0.7 3.2 ± 1.5 1.4 ± 1.0 1.1 ± 1.3
2 AOM/DSS/0.04% Nimesulide 10% 90% 80% 50% 0.1 ± 0.3 2.2 ± 2.3 1.2 ± 0.9 0.6 ± 0.7
3 AOM/DSS/0.05% Troglitazone 20% 90% 50% 30% 0.3 ± 0.7 2.1 ± 2.2 0.7 ± 0.8 0.8 ± 1.6
4 AOM/DSS/0.05% Bezafibrate 30% 80% 60% 20% 0.4 ± 0.7 1.9 ± 1.8 0.9 ± 1.0 0.4 ± 0.8BMC Cancer 2005, 5:46 http://www.biomedcentral.com/1471-2407/5/46
Page 6 of 12
(page number not for citation purposes)
Pathological findings
Macroscopically, nodular, polypoid or caterpillar-like
tumors were observed in the middle and distal colon of
mice in groups 1 through 4. They were histologically tubu-
lar adenoma (Figure 2a) or well-/moderately-differenti-
ated tubular adenocarcinoma (Figure 2b). Dysplasia
(Figure 2c–e) was also developed in mice of these groups.
Animals of groups 5–10 did not have large bowel neo-
plasms and dysplasia. The incidences and multiplicity of
colon neoplasma are shown in Table 2. Group 1 (AOM/
Histopathology of colonic lesions in mice of group 1 Figure 2
Histopathology of colonic lesions in mice of group 1. (a) adenoma, (b) adenocarcinoma, (c) mild dysplasia, and (d) severe dys-
plasia. Hematoxylin and eosin stain. Original magnifications, × 10.
c
d
a bBMC Cancer 2005, 5:46 http://www.biomedcentral.com/1471-2407/5/46
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DSS) induced 100% incidence of colon adenocarcinomas
with a multiplicity of 3.0 ± 1.8. The incidences of colorec-
tal adenocarcinomas in groups 2 (AOM/DSS/0.04%
nimesulide), 3 (AOM/DSS/0.05% troglitazone), and 4
(AOM/DSS/0.05% bezafibrate) were significantly smaller
than that of group 1 (P < 0.01, P < 0.01 and P < 0.05,
respectively). The multiplicities of colon adenocarcino-
mas in groups 2 and 3 were also significantly lower than
that of group 1 (P < 0.005 and P < 0.05, respectively).
While the multiplicity of colon adenocarcinoma of group
4 (AOM/DSS/0.05% bezafibrate) was smaller than group
1, the difference was insignificant. In this study, mucosal
ulcer with or without focal dysplasia (Figure 2c–e) were
also found in the distal colon of mice in groups 1 through
4. The incidences and multiplicity of colonic ulceration
and dysplasia are shown in Table 3. The incidences and
multiplicities of colorectal mucosal ulcer and dysplasia of
groups 2, 3, and 4 were smaller than group 1, but the dif-
ferences did not reach to statistical significance.
Immunohistochemistry for PCNA, ssDNA, β -catenin, COX-
2, iNOS and nitrotyrosine in colonic adenocarcinoma
As summarized in Table 4, PCNA-labeling index (Figure
3a) of colonic adenocarcinomas developed in groups 2, 3,
and 4 was significantly smaller than group 1 (P < 0.001).
Apoptotic index measured by ssDNA immunohistochem-
istry (Figure 3b) in groups 2, 3, and 4 was significantly
greater than group 1 (P < 0.001).
Strong β -catenin expression was seen in the nucleus and
cytoplasm of adenocarcinoma cells (Figure 3c). Although
the intensity was relatively weaker than carcinoma cells,
adenoma cells showed positivity for β -catenin in their
cytoplasm and cell membrane. β -catenin immunoreactiv-
ity was also found in the cell membrane and cytoplasm of
dysplastic cells. Non-lesional cryptal cells showed weak
positivity of β -catenin in their cell membrane. In the pos-
itive cases of COX-2 (Figure 3d), and iNOS (Figure 3e)
expression in the dysplasia and adenocarcinoma, the
staining pattern was granular and localized to cytoplasm
and/or nuclei. Slight immunoreactivity for COX-2 and
iNOS was observed in the superficial layers of the non-
lesional colonic mucosa and in parts of basal layer in all
groups. The expression pattern between COX-2 and iNOS
of colorectal adenocarcinomas was well correlated. Fur-
thermore, a positive staining for nitrotyrosine, a marker of
nitrosative injury, was mainly observed in mononuclear
cells infiltrated in the colonic mucosa (Figure 3f). Neo-
plastic cells also showed negative or very weakly positive
immnoreactivity of nitrotyrosine. Scores for β -catenin,
COX-2 and iNOS expression in colonic adenocarcinomas
are given in Table 4. β -Catenin expression scores of color-
ectal adenocarcinomas in groups 2 and 3 were signifi-
cantly decreased when compared with that in group 1 (P
< 0.05 and P < 0.05, respectively). Scores for COX-2 and
iNOS expression of colorectal adenocarcinomas in groups
2, 3, and 4, were significantly smaller than those in group
1 (P < 0.001). The scores of nitrotyrosine positivity in
groups 2, 3, and 4 were significantly lower than group 1
(P < 0.001).
Discussion
The results of the present work clearly indicated that a
COX-2 inhibitor nimesulide and a PPARγ  ligand troglita-
zone effectively inhibited AOM/DSS-induced colitis-
related colonic carcinogenesis in mice. Inhibitory effect of
Table 4: PCNA and apoptosis indices and scores of β -catenin, COX-2, iNOS and nitrotyrosine expression in colonic adenocarcinomas.
Group Treatment PCNA-labeling Apoptotic Scores for:
no. index (%) index (%) β -Catenin COX-2 iNOS Nitrotyrosine
1 AOM/DSS 62.4 ± 13.7a 
(30)
4.1 ± 1.9 (30) 3.7 ± 0.7 (30) 3.3 ± 0.7 (30) 3.0 ± 1.0 (30) 3.1 ± 0.8 (30)
2 AOM/DSS/
0.04% 
Nimesulide
38.3 ± 11.1 b (6) 11.8 ± 2.9 b (6) 2.3 ± 1.0 c (6) 1.3 ± 0.5 b (6) 1.3 ± 0.5 b (6) 1.7 ± 0.5 b (6)
3 AOM/DSS/
0.05% 
Troglitazone
43.6 ± 9.0 b (9) 10.0 ± 2.4 b (9) 2.7 ± 0.7 c (9) 1.8 ± 0.8 b (9) 1.6 ± 0.5 b (9) 1.8 ± 0.6 b (9)
4 AOM/DSS/
0.05% 
Bezafibrate
40.5 ± 12.7 b 
(15)
9.7 ± 2.7 b (15) 3.0 ± 0.8 (15) 1.8 ± 0.8 b (15) 1.6 ± 0.6 b (15) 2.2 ± 1.1 b (15)
Numbers in parentheses are numbers of lesions examined.
a : means ± SD.
b,c Significantly different from group 1 by Student's t-test (bP < 0.001 and cP < 0.05).BMC Cancer 2005, 5:46 http://www.biomedcentral.com/1471-2407/5/46
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nimesulide was superior to that of troglitazone. Bezafi-
brate also reduced the occurrence of colonic adenocarci-
noma, but the ability was relatively weaker than that of
nimesulide and troglitazone. The suppressive effects of
nimesulide, troglitazone and bezafibrate on the develop-
ment of colonic adenocarcinoma was well correlated with
the inhibition of cell proliferation activity, induction of
apoptosis, and lowered immunoreactivity of β -catenin,
COX-2, iNOS, and nitrotyrosine in the colonic
malignancies. However, no differences on the frequency
of dysplastic lesions could be observed among the groups.
These data may suggest that the pharmacological classes
tested under the present investigation slow down the time
course of tumor development rather than completely pre-
venting it.
The pathogenesis of IBD-associated colorectal carcinogen-
esis is widely believed to involve a step-wise progression
from inflamed and hyperplastic epithelia through flat dys-
plasia to finally adenocarcinoma [30]. IBD-associated
colorectal carcinogenesis is probably promoted by
chronic inflammation, but the mechanism is still unclear.
However, mucosal inflammation may result in colonic
carcinogenesis through several proposed mechanisms
such as induction of genetic mutations, increased-cryptal
cell proliferation, changes in crypt cell metabolism,
changes in bile acid enterohepatic circulation, and altera-
tions in bacteria flora [4,34]. These events are considered
to promote IBD-associated CRC development. Given the
correlation between increased COX-2 expression and
colonic carcinoma and/or inflammation, the chemopre-
ventive effects of NSAIDs seem to be mediated, at least in
part, by COX inhibition [35]. We [36] and others [29,37]
demonstrated that NSAIDs including nimesulide inhib-
ited both colon tumorigenesis and colitis. In the current
study, powerful chemopreventive ability of nimesulide
Immunohistochemistry of PCNA, ssDNA, β -catenin COX-2, iNOS, and nitrotyrosine in mice of group 1 Figure 3
Immunohistochemistry of PCNA, ssDNA, β -catenin COX-2, iNOS, and nitrotyrosine in mice of group 1. (a) PCNA immuno-
histochemistry, (b) ssDNA immunohistochemistry, (c) β -catenin immunohistochemistry, (d) COX-2 immunohistochemistry, 
(e) iNOS immunohistochemistry, and (f) nitrotyrosine immunohistochemistry. Original magnifications: a, d, e, f, × 10; c, × 20; b, 
× 40. Insets, immunohistochemistry staining for each antibody in the mouse colon from group 10 (Original magnifications, × 
10).
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was observed in our colitis-related mouse colon carcino-
genesis model, suggesting that nimesulide can be applied
as an effective chemopreventor of both sporadic and IBD-
associated cololectral carcinogenesis.
We previously demonstrated that dietary administration
of PPARα  and PPARγ  ligands inhibits AOM and/or DSS-
induced ACF in rodents [38]. In the present study, cancer
chemopreventive ability of the PPARγ  ligand,
troglitazone, or the PPARα  ligand, bezafibrate, was found
in AOM/DSS-induced mouse colon carcinogenesis
model, although their ability was lower than nimesulide.
Inhibition of colonic inflammation and decrease in cell
proliferation activity by these PPARs ligands might be
responsible for their chemopreventive effects on colitis-
associated colon carcinogenesis [38]. DNA damage
caused by reactive oxygen and nitrogen species may con-
tribute to colitis-related colon tumorigenesis [39]. Several
NSAIDs can bind to PPARα  and PPARγ  [40]. Their anti-
inflammatory activities might be mediated through inhi-
bition of COX-1 and/or COX-2. PPARα  could suppress
COX-2 induction [41]. In addition, immunomodulation
by the PPARs ligands might contribute to inhibition of
colitis and colon carcinogenesis [42].
Expression and activity of iNOS is increased in colonic
mucosa in patients with IBD [43] and colonic adenomas
[44]. Several studies using experimental colon carcinogen-
esis models indicate that chemically induced colon
tumors have higher expression and/or activity of iNOS
compared with those in their adjacent non-tumorous tis-
sues [12,25]. Numerous iNOS-positive and nitrotyrosine-
positive inflammatory cells are observed in non-cancer-
ous colonic mucosa of mice treated with DSS [25]. PPARα
[45] and PPARγ  [46] involve in inflammation control,
and can inhibit iNOS expression [47]. In addition, Rao et
al. [48] showed that an iNOS-selective inhibitor
suppresses AOM-induced colonic ACF development and
iNOS activity. Furthermore, nitrotyrosine may originate
from the reaction of iNOS generated NO with reactive
oxygen species [49] or the myeloperoxidase-dependent
pathway [50]. In the present study, we found a positive
immunoreactivity for iNOS and nitrotyrosine in the
inflamed colon, suggesting the formation of peroxynitrite
and other NO-derived oxidants. These results may suggest
that one of the mechanisms by which tested agents exert
chemopreventive ability might be related to suppression
of iNOS activity and/or expression.
Cell proliferation plays an important role in multi-step
carcinogenesis [51]. In the colon, the number of cryptal
cells is strictly regulated by a balance between cell
proliferation and cell death that maintains homeostasis
[52]. Changes in cell proliferation and apoptosis are
regarded as a common denominator in the pathogenesis
of tumor formation [53]. Reduced tumor incidence is gen-
erally associated with decreases in cellular proliferation
and/or increases in apoptosis [54]. An increased COX-2
expression in CRC [55,56] may confer a survival advan-
tage on cells by inhibition of apoptosis and a change in
cellular adhesion to the extracellular matrix [57]. Cancer
cells treated with PPARγ  ligands induce cell differentiation
and apoptosis [14,17]. Recently, Tardieu et al. [58] dem-
onstrated that nimesulide increases apoptosis in colonic
mucosa of DSS-treated rats. Our findings that nimesulide
and troglitazone inhibited cell proliferation activity and
induced apoptosis in colorectal mucosa are in accordance
with these findings. Thus, cellular responses like cell
growth and/or apoptosis to nimesulide and troglitazone
may contribute to chemopreventive effects against colon
carcinogenesis processes.
β -Catenin is a key regulator of the cadherin-mediated cell-
cell adhesion system and an important element in the
Wnt signal transduction pathway [59]. Accumulated β -
catenin interacts with T-cell factor (Tcf) or lymphoid-
enhancer factor (Lef) and translocates to the nucleus, in
which it transactivates target genes including c-myc and
cyclin D1 that are the potentially oncogenic [47,60] in the
cytoplasm or nucleus as a consequence of mutant Apc or
β -catenin  genesis frequently observed in early stages of
colorectal carcinogenesis [61,62]. Recently, Girnun et al.
[21] indicated that a ligand of PPARγ  suppresses β -catenin
levels and colon carcinogenesis in Pparγ +/- mice treated
with AOM. Furthermore, COX-2 is regulated by nuclear β -
catenin accumulation [63]. In the current study, treatment
with nimesulide, troglitazone, and bezafibrate signifi-
cantly suppressed β -catenin expression in colorectal aden-
ocarcinomas. Thus, it seems likely that the preventive
efficacies of the COX-2 inhibitor (nimesulide) or the
PPAR ligands (troglitazone and bezafibrate) against
AOM/DSS induced mouse colon carcinogenesis might be
mediated, at least in part, by β -catenin down-regulation.
Chemoprevention of cancer might be defined as the delib-
erate introduction of these selected non-toxic substances
into the diet for the purpose of reducing cancer develop-
ment. In the present study, the mean liver weights of mice
in dietary feeding of troglitazone and bezafibrate were sig-
nificantly increased. However, there were no pathological
alterations suggesting toxicity of the drugs examined. It is
known that administration of PPARs ligands to rodent
exhibit hepatomegaly due to both cellular hypertrophy
and hyperplasia [64]. Increase in liver weight by exposure
of troglitazone and bezafibrate in this study may be
caused by these pathological changes. The estimated daily
intakes of nimesulide, troglitazone, and bezafibrate in
mice given the diets containing 400 ppm and 500 ppm
were approximately 160 mg/kg and 200 mg/kg in the
present study. In a direct extrapolation to a 60 kg person,BMC Cancer 2005, 5:46 http://www.biomedcentral.com/1471-2407/5/46
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these doses are slightly lower than those of clinical trial
[65-67]. These findings may suggest that the efficacy of
these agents at dietary dose-levels has a direct practical
and translational relevance to human.
Conclusion
In conclusion, dietary administration of nimesulide, tro-
glitazone, and bezafibrate could effectively suppress colon
carcinogenesis induced by AOM and DSS in female ICR
mice. Our on-going study on molecular profiles in colonic
samples from the current experiment will provide precise
molecular mechanisms involved in their inhibitory action
in AOM/DSS-induced mouse colon carcinogenesis.
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